BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Bukwang Pharma receives FDA approval for dyskinesia drug trial

14 February 2020 | News

The approved trial will be conducted in about 30 institutions in the United States

South Korea based Bukwang Pharmaceuticals recently announced that the US Food and Drug Administration (FDA) has approved a phase 2 trial of JM-010.

JM-010 is a new drug candidate developed by Danish Bioventure Contera Pharma, a subsidiary of Bukwang Pharmaceutical.

The approved trial will be conducted in about 30 institutions in the United States to evaluate the safety and effectiveness of JM-010 in 190 patients with side effects of dyskinesia caused by Parkinson's disease. Dyskinesia is uncontrolled, involuntary movement that may occur with long-term levodopa use and longer time with Parkinson's.

As JM-010 is entering the global clinical stage, it is already well-proven and plans to enter the KOSDAQ through the technology listing of foreign companies.